Chiron Launches Proleukin in South Korea; Proprietary Cancer Treatment Now Approved in 47 Countries.EMERYVILLE, Calif.--(BW HealthWire)--Aug. 12, 1998--Chiron Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CHIR CHIR Chiricahua National Monument (US National Park Service) ) today announced that Proleukin (aldesleukin) for injection was approved by the South Korean Food and Drug Administration for the treatment of patients with metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. . Proleukin, a recombinant form of the naturally occurring immune modulator Modulator Any device or circuit by means of which a desired signal is impressed upon a higher-frequency periodic wave known as a carrier. The process is called modulation. The modulator may vary the amplitude, frequency, or phase of the carrier. interleukin-2 (IL-2), is now approved for sale in 47 countries worldwide. Hyup Jin Corporation, based in Seoul, will exclusively distribute and market Proleukin in South Korea. Chiron Ltd will own the product license and import product. "This marks Chiron's first major product launch in Asia and is a significant step in further developing our global oncology business. We believe that South Korea, with the second largest oncology market in the region, represents an important commercial opportunity," said Magnus Lundberg, president of Chiron Therapeutics and Chiron Vaccines. "Our partner, Hyup Jin, has done an outstanding job. In less than a year since signing the distribution contract, they have been able to register and launch Proleukin." Hyup Jin is now commencing sales activities in South Korea with leading cancer specialists and hospitals. In the fall, a lecture tour is planned for Martin Gore, M.D., a leading investigator from The Royal Marsden Hospital in London. Dr. Gore will present his extensive experience with Proleukin and review the latest data from U.S. and European investigators. Chiron Corporation Chiron Corporation was a multinational biotechnology firm based in Emeryville, California that was acquired by Novartis International AG on April 20 2006. It had offices and facilities in eighteen countries on five continents. , headquartered in Emeryville, is a leading biotechnology company that participates in three global healthcare markets: diagnostics, therapeutics and vaccines. Chiron also conducts research and development in the fields of biological proteins, gene therapy and combinatorial chemistry.
CONTACT: Chiron Corporation
Jim Knighton, 510/923-6055
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion